Rheumatology
Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data
Seung Min Jung, Seung-Ki Kwok, Ji Hyeon Ju, Yong-Beom Park, Sung-Hwan Park
Korean J Intern Med. 2019;34(3):669-677. Published online November 29, 2017
Background/Aims: Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain. The aim of this study was to evaluate cancer risk in RA patients treated with TNF inhibitors (TNFi), based on Korean Nationwide Health Insu..
|